Interviews with Pharma and Biotech Global Leaders
Refine Search
Pharmaceutical
The UK’s Vaccines Manufacturing Innovation Centre (VMIC) is not due to open until 2022, but its first permanent chief executive has already been announced. 4 September 2019
Pharmaceutical
UK-based Mundipharma is a unique player in healthcare, with Marco Cerato, its senior vice president, business development and strategic partnerships, telling The Pharma Letter that it “has always functioned slightly differently to other pharma companies.” 19 August 2019
Pharmaceutical
Ensuring that the actions, messages and objectives of pharma companies and representative national and regional associations are aligned with the needs of patients and health systems in Latin America. 16 August 2019
Biotechnology
Last year, Denmark-headquartered dermatology specialist LEO Pharma increased the size of its investment in R&D to 18%, compared to the 15% of the previous year. 25 July 2019
Biotechnology
As the global medical lead of the Adcetris (brentuximab vedotin) program for Japanese pharma major Takeda, Thanos Zomas’ job was made easier by Phase III trial results that he describes as “almost unprecedented.” 22 July 2019
Pharmaceutical
With marketing expenses stretching into the tens or even hundreds of millions of dollars, launching a new product can be a huge challenge for small pharmaceutical companies. 12 July 2019
Biosimilars
For biosimilar companies in Europe, data showing the savings that their products are delivering are becoming just as important as findings on biosimilarity. 5 July 2019
Biotechnology
Europe's biggest privately-held biotech BioNTech has been in the news recently, with reports the company could be about to raise just shy of a billion dollars in a US listing. 25 June 2019
Biotechnology
For Belgium-based drugmaker UCB, EULAR 2019 came at a good time to shed further new light on bimekizumab – which the company itself is billing as its pipeline molecule – in a couple of the indications in which it is showing significant promise. 21 June 2019
Pharmaceutical
Germany’s Merck KGaA has been building a multi-dimensional ecosystem with its two pharmaceutical sectors - healthcare (formerly known as Merck Serono) and life sciences - to propel its future advances in China. 13 June 2019
Pharmaceutical
Marta Diez is the first woman president of Cámara de la Innovación Farmacéutica (CIF), a group representing 23 pharma multinationals with a presence in Chile. 12 June 2019
Biotechnology
As the dust settles on this year’s annual meeting of the American Society of Clinical Oncology (ASCO), analysts have a lot of promising data to digest. 7 June 2019
Biotechnology
As industry majors prepare to make a splash at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), 2003-founded nanomedicine specialist Nanobiotix hopes it can punch above its weight. 24 May 2019
Biotechnology
When it comes to long-term investment in pharma stocks, looking at pipeline assets at a pre-clinical or early clinical stage gives as good a clue as any as to where the value lies. 17 May 2019
Pharmaceutical
Learning from the standards set by the USA, Europe and Brazil, Colombia is fast catching up in making the country an attractive place to research, seek approval for and market medicines, according to Yaneth Giha Tovar, executive president of AFRIDO, the national trade association for the pharmaceutical industry. 13 May 2019
Biosimilars
Swiss pharma giant Roche’s non-Hodgkin’s lymphoma treatment MabThera (rituximab) is facing a strong rival in China - its biosimilar version Hanlikang from Fosun Pharma’s biotech arm Henlius. 7 May 2019
Biotechnology
Biotech major Amgen on April 9 announced it had received US Food and Drug Administration approval for its osteoporosis treatment Evenity (romosozumab), nearly three months after the Japan approval. 17 April 2019
Pharmaceutical
Canada-based Canopy Growth is the world’s largest cannabis company, by market cap, and it aspires to be a world leader in developing the drug as a medicine. 17 April 2019
Generics
The end of a drug’s exclusivity period can result in expensive patent litigation, and IP lawyer Kent Walker has identified an emerging trend that could present a solution for generic challengers seeking to enter the market. 18 March 2019
Pharmaceutical
Aspirin may be over 100 years old, but OtiTopic believes the potential of the analgesic workhorse to provide innovative therapies is yet to be exhausted. 1 March 2019
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze